This is the first positive Phase 3 trial of a HIF-2 alpha inhibitor in combination with a multi-targeted tyrosine kinase inhibitor, the first for patients with RCC whose disease progressed on or after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results